BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 28625622)

  • 1. PD-L1 expression in neuroendocrine tumors of the lung.
    Tsuruoka K; Horinouchi H; Goto Y; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Asakura K; Nakagawa K; Sakurai H; Watanabe SI; Tsuta K; Ohe Y
    Lung Cancer; 2017 Jun; 108():115-120. PubMed ID: 28625622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor.
    Inamura K; Yokouchi Y; Kobayashi M; Ninomiya H; Sakakibara R; Nishio M; Okumura S; Ishikawa Y
    Cancer Med; 2017 Oct; 6(10):2347-2356. PubMed ID: 28925087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
    Guleria P; Kumar S; Malik PS; Jain D
    Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
    Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
    Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival.
    Skov BG; Holm B; Erreboe A; Skov T; Mellemgaard A
    J Thorac Oncol; 2010 Apr; 5(4):453-9. PubMed ID: 20104194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 expression in large cell neuroendocrine carcinoma of the lung.
    Eichhorn F; Harms A; Warth A; Muley T; Winter H; Eichhorn ME
    Lung Cancer; 2018 Apr; 118():76-82. PubMed ID: 29572007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
    Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1).
    Shimoji M; Shimizu S; Sato K; Suda K; Kobayashi Y; Tomizawa K; Takemoto T; Mitsudomi T
    Lung Cancer; 2016 Aug; 98():69-75. PubMed ID: 27393509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation.
    von Hardenberg J; Hartmann S; Nitschke K; Worst TS; Ting S; Reis H; Nuhn P; Weis CA; Erben P
    Clin Genitourin Cancer; 2019 Apr; 17(2):145-153.e5. PubMed ID: 30709785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung.
    Kim HS; Lee JH; Nam SJ; Ock CY; Moon JW; Yoo CW; Lee GK; Han JY
    J Thorac Oncol; 2018 May; 13(5):636-648. PubMed ID: 29378266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
    Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
    Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of PD-L1 Expression in Tumor Tissue of Patients with Lung Carcinoma and Correlation with Clinical and Demographic Data.
    Dix Junqueira Pinto G; de Souza Viana L; Scapulatempo Neto C; Vicente Serrano S
    J Immunol Res; 2016; 2016():9839685. PubMed ID: 27747247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
    Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M
    Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hASH1 is a specific immunohistochemical marker for lung neuroendocrine tumors.
    Ye B; Cappel J; Findeis-Hosey J; McMahon L; Yang Q; Xiao GQ; Xu H; Li F
    Hum Pathol; 2016 Feb; 48():142-7. PubMed ID: 26596584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer.
    Yu H; Batenchuk C; Badzio A; Boyle TA; Czapiewski P; Chan DC; Lu X; Gao D; Ellison K; Kowalewski AA; Rivard CJ; Dziadziuszko R; Zhou C; Hussein M; Richards D; Wilks S; Monte M; Edenfield W; Goldschmidt J; Page R; Ulrich B; Waterhouse D; Close S; Jassem J; Kulig K; Hirsch FR
    J Thorac Oncol; 2017 Jan; 12(1):110-120. PubMed ID: 27639678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine tumors of the lung: A five-year retrospective experience of Egyptian NCI (2010-2014).
    Saber M; Ismail Y; Alieldin N; Loay I; El Zawahry M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):151-158. PubMed ID: 30470605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors.
    Kasajima A; Ishikawa Y; Iwata A; Steiger K; Oka N; Ishida H; Sakurada A; Suzuki H; Kameya T; Konukiewitz B; Klöppel G; Okada Y; Sasano H; Weichert W
    Endocr Relat Cancer; 2018 Mar; 25(3):339-350. PubMed ID: 29326364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary neuroendocrine tumors: study of 90 cases focusing on clinicopathological characteristics, immunophenotype, preoperative biopsy, and frozen section diagnoses.
    Yeh YC; Chou TY
    J Surg Oncol; 2014 Mar; 109(3):280-6. PubMed ID: 24301337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.